Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route-Reference-Cited by-同舟云学术

Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route

Published:2021-05-17 Issue:10 Volume:64 Page:6902-6923
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Vyskocil Stepan^ORCID,Cardin David,Ciavarri Jeffrey,Conlon Joe,Cullis Courtney,England Dylan,Gershman Rachel,Gigstad Kenneth,Gipson Krista,Gould Alexandra,Greenspan Paul,Griffin Robert,Gulavita Nanda,Harrison Sean,Hu Zhigen,Hu Yongbo,Hata Akito,Huang Jian,Huang Shih-Chung,Janowick Dave,Jones Matthew,Kolev Vihren,Langston Steven P.^ORCID,Lee Hong Myung,Li Gang,Lok David,Ma Liting,Mai Doanh,Malley Jenna,Matsuda Atsushi,Mizutani Hirotake,Mizutani Miho,Molchanova Nina,Nunes Elise,Pusalkar Sandeep,Renou Christelle,Rowland Scott,Sato Yosuke,Shaw Michael,Shen Luhua,Shi Zhan,Skene Robert¹,Soucy Francois,Stroud Steve,Xu He,Xu Tianlin,Abu-Yousif Adnan O.,Zhang Ji

Affiliation:

1. Drug Discovery Sciences, Takeda Pharmaceuticals International Company, 9625 Towne Centre Drive, San Diego, California 92121, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.1c00374

Reference40 articles.

1. Immune checkpoint inhibitors: recent progress and potential biomarkers

2. Combination Cancer Therapy with Immune Checkpoint Blockade: Mechanisms and Strategies

3. Tumor Cell-Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy